Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABT 
Abbott Laboratories (ABT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: ABT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $144.47
1 Year Target Price $144.47
| 12 | Strong Buy |
| 7 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.78% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 214.96B USD | Price to earnings Ratio 15.53 | 1Y Target Price 144.47 |
Price to earnings Ratio 15.53 | 1Y Target Price 144.47 | ||
Volume (30-day avg) 28 | Beta 0.7 | 52 Weeks Range 109.21 - 139.33 | Updated Date 11/2/2025 |
52 Weeks Range 109.21 - 139.33 | Updated Date 11/2/2025 | ||
Dividends yield (FY) 1.89% | Basic EPS (TTM) 7.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-15 | When Before Market | Estimate 1.3 | Actual 1.3 |
Profitability
Profit Margin 31.88% | Operating Margin (TTM) 19.4% |
Management Effectiveness
Return on Assets (TTM) 6.79% | Return on Equity (TTM) 30.62% |
Valuation
Trailing PE 15.53 | Forward PE 23.36 | Enterprise Value 237618644271 | Price to Sales(TTM) 4.9 |
Enterprise Value 237618644271 | Price to Sales(TTM) 4.9 | ||
Enterprise Value to Revenue 5.51 | Enterprise Value to EBITDA 20.54 | Shares Outstanding 1738871947 | Shares Floating 1728630712 |
Shares Outstanding 1738871947 | Shares Floating 1728630712 | ||
Percent Insiders 0.54 | Percent Institutions 80.6 |
Upturn AI SWOT
Abbott Laboratories
Company Overview
History and Background
Abbott Laboratories was founded in 1888 by Dr. Wallace Calvin Abbott as the Abbott Alkaloidal Company. It initially focused on manufacturing precise-dosage medicines. Over time, it expanded into diagnostics, medical devices, and nutritional products.
Core Business Areas
- Established Pharmaceutical Products: Generic pharmaceuticals sold outside the U.S.
- Diagnostics: A range of diagnostic systems and tests for hospitals, labs, and point-of-care settings.
- Medical Devices: Medical devices for cardiac care, neuromodulation, and diabetes care.
- Nutrition: Nutritional products including infant formula, adult nutrition, and sports nutrition.
Leadership and Structure
Robert B. Ford is the current Chairman and CEO. Abbott operates with a divisional structure, with each business segment having its own leadership team. The board of directors provides oversight.
Top Products and Market Share
Key Offerings
- FreeStyle Libre: A continuous glucose monitoring (CGM) system. The FreeStyle Libre platform holds a significant market share in the CGM market. Competitors include Dexcom (DXCM) and Medtronic (MDT). Revenue for Diabetes Care (primarily FreeStyle Libre) was a significant portion of overall sales.
- Similac: Infant formula. Similac competes with brands like Enfamil (Reckitt Benckiser) and Gerber (Nestlu00e9). Similac sales were impacted by product recalls in the past.
- Ensure: Adult nutritional drink. Ensure competes with brands like Boost (Nestlu00e9) and other store brands. Ensure maintains a strong position in the adult nutrition market.
- Alinity: A family of diagnostic instruments. Alinity faces competition from Roche (RHHBY) and Siemens Healthineers (SIEGY).
Market Dynamics
Industry Overview
The healthcare industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology.
Positioning
Abbott is a diversified healthcare company with a strong presence in diagnostics, medical devices, nutrition, and pharmaceuticals. Its diversified portfolio provides stability and allows it to capitalize on various growth opportunities.
Total Addressable Market (TAM)
The global healthcare market is estimated to be worth trillions of dollars. Abbott is positioned to capture a significant share of this TAM through its diverse portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong brand reputation
- Global presence
- Robust R&D capabilities
- Established distribution network
Weaknesses
- Exposure to regulatory risks
- Dependence on key products
- Product recalls and manufacturing issues
- Competition from larger players
Opportunities
- Growing demand for diagnostics and medical devices
- Expansion into emerging markets
- Strategic acquisitions and partnerships
- Development of innovative products
- Increasing prevalence of chronic diseases
Threats
- Intense competition
- Pricing pressures
- Changes in healthcare regulations
- Economic downturns
- Patent expirations
Competitors and Market Share
Key Competitors
- JNJ
- DHR
- BSX
- MDT
- BDX
Competitive Landscape
Abbott faces intense competition from other large healthcare companies. Its diversified portfolio and global presence provide it with a competitive advantage, but it needs to continue to innovate and adapt to changing market conditions.
Major Acquisitions
St. Jude Medical
- Year: 2017
- Acquisition Price (USD millions): 25000
- Strategic Rationale: Expanded Abbott's cardiovascular device portfolio and strengthened its position in the medical device market.
Growth Trajectory and Initiatives
Historical Growth: Abbott has experienced moderate revenue growth in recent years, driven by acquisitions and organic growth in its key business segments.
Future Projections: Analysts project continued revenue growth for Abbott, driven by demand for its diagnostics and medical devices. Earnings growth is expected to be solid as well.
Recent Initiatives: Abbott has been actively pursuing strategic acquisitions to expand its product portfolio and geographic reach. It is also investing heavily in R&D to develop innovative products.
Summary
Abbott Laboratories is a well-established healthcare company with a diversified portfolio and global presence. The company's strengths lie in its established brands, strong R&D, and consistent dividend payouts. Challenges include competition, regulatory hurdles, and the potential for product recalls. Continued innovation and strategic acquisitions will be crucial for maintaining its competitive edge.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Abbott Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Market Research Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abbott Laboratories
Exchange NYSE | Headquaters North Chicago, IL, United States | ||
IPO Launch date 1978-01-13 | Chairman of the Board, President & CEO Mr. Robert B. Ford | ||
Sector Healthcare | Industry Medical Devices | Full time employees 114000 | Website https://www.abbott.com |
Full time employees 114000 | Website https://www.abbott.com | ||
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.